Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 2d ago
SVB Securities Remains a Buy on Roivant Sciences (ROIV)
TipRanks · 3d ago
PENN, ALT and HA are among after hour movers
Seeking Alpha · 6d ago
Analyst Expectations for Roivant Sciences's Future
Benzinga · 03/16 17:01
Roivant Sciences (ROIV) Receives a Buy from H.C. Wainwright
TipRanks · 03/16 10:35
Roivant Sciences (ROIV) Gets a Buy from Citigroup
TipRanks · 03/16 09:45
Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years
Benzinga · 03/15 16:13
Roivant's Stock Rallies On New Data For Dermatitis Drug -- MarketWatch
MarketWatch · 03/15 14:29
Roivant stock jumps as skin cream Vtama meets main goal of phase 3 eczema trial
Seeking Alpha · 03/15 12:37
BRIEF-Roivant Reports Positive Topline Results From ADORING 2 Atopic Dermatitis Phase 3 Trial Of VTAMA Cream
Reuters · 03/15 12:02
Roivant Announces Phase 3 Trial Of VTAMA Achieved Primary Endpoint And All Secondary Endpoints
Benzinga · 03/15 11:46
Roivant Sciences Unit Dermavant Sees 'Positive' Results From Phase 3 Study of Vtama Cream to Treat Atopic Dermatitis
Roivant Sciences Unit Dermavant Sees 'Positive' Results From Phase 3 Study of Vtama Cream to Treat Atopic Dermatitis
MT Newswires · 03/15 10:28
BRIEF-Roivant To Host Investor Call At 800 Am Et On Wednesday, March 15 To Review Results From Adoring 2 Phase 3 Trial In Atopic Dermatitis
Reuters · 03/14 22:53
Moderna loses bid to shift liability in COVID-19 vaccine patent case
Reuters · 03/10 23:31
SVB Securities Sticks to Their Buy Rating for Roivant Sciences (ROIV)
TipRanks · 03/09 04:05
BRIEF-Covant Therapeutics Announces Formation Of Its Scientific Advisory Board To Support Platform And Pipeline Advancement
Reuters · 03/07 13:15
Roivant Sciences: 'Fiercely Economic Actor' With Multiple Catalysts
Seeking Alpha · 03/06 19:38
Cantor Fitzgerald Sticks to Its Buy Rating for Roivant Sciences (ROIV)
TipRanks · 03/02 16:15
Prometheus Biosciences: Profit Taking Lurking Ahead
Seeking Alpha · 02/28 22:59
Webull provides a variety of real-time ROIV stock news. You can receive the latest news about Roivant Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ROIV
Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.